Publications

5532 Results

Phase III study of intraperitoneal (IP) cisplatin (CDDP)/intravenous (IV) cyclophosphamide (CPA) vs IV CDDP/IV CPA in patients (pts) with optimal disease stage III ovarian cancer: A SWOG-GOG-ECOG Intergroup Study (INT-0051)

Authors
DS Alberts;PY Liu;EV Hannigan;R O'Toole;SD Williams;J Young;EW Franklin;D Clarke-Pearson;VK Malviya;S DuBeshter;W Hoskins;M Adelson;RD Alvarez;S Vogel;J O'Sullivan;DJ Garcia;D Sparks;ML Rothenberg
Journal / Conference
ASCO 14:273(#760)
Year
1995
Research Committee(s)
Gynecologic
Study Number(s)
SWOG-8501 (INT-0051)

A Southwest Oncology Group (SWOG) analysis of the anaplastic large cell lymphoma (ALCL) entities in the revised European American lymphoma (REAL) classification.

Authors
T Grogan;C Kjeldsberg;R Tubbs;S Dahlberg;R Braziel;C Foucar;C Leith;C Spier;E Gaynor;T Miller;R Fisher
Journal / Conference
International Academy of Pathology Book of Abstracts :111A(#644)
Year
1995
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8516 (INT-0067), SWOG-8819

Tumor infiltrating lymphocytes (TILs) instage I cutaneous melanoma: A Southwest Oncology Group study.

Authors
RJ Tuthill;DJ Rector;VK Sondak;PY Liu;FL Meyskens
Journal / Conference
International Academy of Pathology Book of Abstracts :51A(#284)
Year
1995
Research Committee(s)
Melanoma
Study Number(s)
SWOG-8049

Evaluation of multimodality treatment of locoregional esophageal carcinoma: SWOG 9060.

Authors
E Poplin;A Herskovic;J Jacobson;T Panella;J Macdonald
Journal / Conference
ASCO 14:202(#486)
Year
1995
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-9060

Elevated serum CA-125: An adverse prognostic factor for survival in epithelial ovarian cancer (EOC) with minimal residual disease after second-look laparotomy (SLL)

Authors
F Muggia;PY Liu;DS Alberts;K Terada;RJ Belt;HJ Schmidt;TW Pollock;EB Weiser;DW Blayney;D Wallace;R O'Toole
Journal / Conference
ASCO 14:270(#750)
Year
1995
Research Committee(s)
Gynecologic
Study Number(s)
SWOG-8835

Survival and response to treatment in patients (pts) with metastatic melanoma from intraocular primaries (MMIP) on SWOG studies.

Authors
K Katato;PY Liu;V Sondak;LE Flaherty
Journal / Conference
ASCO 14:410(#1298)
Year
1995
Research Committee(s)
Melanoma
Study Number(s)
SWOG-8107, SWOG-8118, SWOG-8324, SWOG-8723, SWOG-8754, SWOG-8804, SWOG-8921

Phase II trial of piroxantrone in disseminated malignant melanoma: A Southwest Oncology Group study.

Authors
J Sosman;PY Liu;A Hantel;L Flaherty;V Sondak
Journal / Conference
ASCO 14:418(#1330)
Year
1995
Research Committee(s)
Melanoma
Study Number(s)
SWOG-9116

Autologous bone marrow transplantation (ABMT) for patients with diffuse non-Hodgkin's lymphoma: Value of augmented preparative regimens. A Southwest Oncology Group (SWOG) trial.

Authors
P Stiff;S Dahlberg;RI Fisher;A McCall;A Nademanee;SJ Forman;S Horning;K Blume
Journal / Conference
ASCO 14:388(#1209)
Year
1995
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8942

The prognostic significance of prostate specific antigen (PSA) in stage D2 prostate cancer (PC) interim evaluation of Intergroup study 0105

Authors
M Eisenberger;ED Crawford;D McLeod;M Hussain;P Loehrer;B Blumentstein
Journal / Conference
ASCO 14:235(#613)
Year
1995
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8894 (INT-0105) (EST-2889)

Phase II study of taxol in patients (pts) with recurrent malignant glioma: North American Brain Tumor Consortium

Authors
M Prados;C Schold;A Spence;M Berger;L McAllister;M Mehta;M Gilbert;D Fulton;S Chang
Journal / Conference
ASCO 14:146(#281)
Year
1995
Research Committee(s)
Gastrointestinal
Study Number(s)
SWOG-9401 (NCCTG-90-46-52)